Fibrotic processes are the underlying factors in a variety of difficult-to-treat diseases, resulting in progressive organ failure. Severe organ failure can also be triggered by acute tissue injury. Agomab aims to resolve these processes through its broad pipeline of antibody and small molecule compounds designed for their unique and novel mode of actions against well-validated and potentially disease modifying targets, ultimately leading to repair of tissue injury, resolution of fibrosis and restoration of organ function.